OncoMatch/Clinical Trials/NCT05433142
Study of XmAb®819 in Subjects With Advanced Clear Cell Renal Cell Carcinoma
Is NCT05433142 recruiting? Yes, currently enrolling (May 2026). This Phase 1 trial studies XmAb819 for clear cell renal cell carcinoma.
Treatment: XmAb819 — The purpose of this study is to assess the safety and tolerability of XmAb®819 administered intravenous (IV) or subcutaneous (SC) in subjects with relapsed or refractory clear cell renal cell carcinoma and to identify the minimum safe and biologically active dose and the recommended dose (RD).
Check if I qualifyExtracted eligibility criteria
Cancer type
Renal Cell Carcinoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Must have received: standard-of-care therapies
relapsed and refractory ccRCC, pRCC, NSCLC, and CRC with evidence of disease progression on standard-of-care therapies
Cannot have received: investigational anti-ENPP3/CD203c therapy
Prior treatment with an investigational anti-ENPP3/CD203c therapy
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- Xencor Investigative Site · Phoenix, Arizona
- Xencor Investigative Site · Duarte, California
- Xencor Investigative Site · Sacramento, California
- Xencor Investigative Site · New Haven, Connecticut
- Xencor Investigative Site · Jacksonville, Florida
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify